A Dipeptidyl Peptidase 4 (DPP-4) Inhibitor in Type 1 Diabetes

Trial Profile

A Dipeptidyl Peptidase 4 (DPP-4) Inhibitor in Type 1 Diabetes

Phase of Trial: Phase IV

Latest Information Update: 23 Mar 2017

At a glance

  • Drugs Saxagliptin (Primary) ; Insulin
  • Indications Type 1 diabetes mellitus
  • Focus Pharmacodynamics
  • Most Recent Events

    • 07 Dec 2015 Primary endpoint (Adrenaline levels) has not been met as results published in the Diabetic Medicine.
    • 07 Dec 2015 Results published in the Diabetic Medicine
    • 17 Oct 2013 Status changed from recruiting to active, no longer recruiting as reported by United Kingdom Clinical Research Network record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top